A 23-year-old female developed Thrombotic thrombocytopenic purpura (TTP) symptoms three days after the second dose of CoronaVac.
A 45-year-old female experienced TTP symptoms five days after the second dose of CoronaVac.
A study from Nanjing, China, showed an increase in TTP cases from 2019 to 2022, which coincided with the initiation of COVID-19 vaccination campaigns.
While the incidence of TTP is rare, the observed increase raises concerns about a potential association with vaccination.
Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathic hemolytic anemia
CoronaVac, also known as the Sinovac COVID-19 vaccine, was a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
The study suggests that COVID-19 vaccines may trigger an autoimmune response that cross-reacts with ADAMTS13, a crucial protein involved in blood clotting.
A deficiency in ADAMTS13 can lead to TTP, a rare but serious blood clotting disorder.
While this study highlights a potential association between CoronaVac and TTP, it is essential to note that more research is needed to establish a definitive causal link.
TTP is a rare condition, and the risk associated with COVID-19 vaccination must be weighed against the benefits of protection from severe COVID-19 illness.
COMMENTS